Stanton B.E. Hector

Dr. Stanton B.E. Hector


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Fuel
Verified
Journal Article
Closed access
CLChangzhu Li
Changzhu Li
JMJiangshan Ma
Jiangshan Ma
ZXZhihong Xiao
Zhihong Xiao
SHStanton B.E. Hector
Stanton B.E. Hector
RLRukuan Liu
Rukuan Liu
QLQiang Liu
Qiang Liu

1 September 2020 in Epigenomes
Verified
Journal Article
Open access
PDF file
Wendy SolomonWendy Solomon
Wendy Solomon
SHStanton B.E. Hector
Stanton B.E. Hector
Shanel RaghubeerShanel Raghubeer
Shanel Raghubeer
RERajiv Erasmus
Rajiv Erasmus
AKAndre Pascal Kengne
Andre Pascal Kengne
TMTandi E Matsha
Tandi E Matsha
Metformin, which is used as a first line treatment for type 2 diabetes mellitus (T2DM), has been shown to affect epigenetic patterns. In this study, we investigated the DNA methylation and potential lncRNA modifications in metformin-treated and newly diagnosed adults with T2DM. Genome-wide DNA methylation and lncRNA analysis were performed from the peripheral blood of 12 screen-detected and 12 metformin-treated T2DM individuals followed by gene ontology (GO) and KEGG pathway analysis. Differentially methylated regions (DMRs) observed showed 22 hypermethylated and 11 hypomethylated DMRs between individuals on metformin compared to screen-detected subjects. Amongst the hypomethylated DMR regions were the SLC gene family, specifically, SLC25A35 and SLC28A1. Fifty-seven lncRNA-associated DNA methylation regions included the mitochondrial ATP synthase-coupling factor 6 (ATP5J). Functional gene mapping and pathway analysis identified regions in the axon initial segment (AIS), node of Ranvier, cell periphery, cleavage furrow, cell surface furrow, and stress fiber. In conclusion, our study has identified a number of DMRs and lncRNA-associated DNA methylation regions in metformin-treated T2DM that are potential targets for therapeutic monitoring in patients with diabetes.

13 May 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
GDGlenda Mary Davison
Glenda Mary Davison
TMTandi E Matsha
Tandi E Matsha
Shanel RaghubeerShanel Raghubeer
Shanel Raghubeer
SHStanton B.E. Hector
Stanton B.E. Hector
SDSaarah Davids
Saarah Davids
YPYvonne Prince
Yvonne Prince
The oral cavity is home to a diverse community of microbiota comprising bacteria, viruses, protozoa, and fungi. These microorganisms inhabit several oral niches and play a significant role in supporting both oral and systemic health. The fine balance between the microbial communities can be influenced by genetics and environmental factors, potentially leading to dysbiosis. Alterations in the oral microbiota have been implicated in periodontitis, chronic inflammation, and systemic disease. Tobacco has been identified as a major player in altering the oral microenvironment and disturbing the balance between potentially pathogenic and beneficial commensals. The resulting dysbiosis promotes inflammation and assists in the passage of pathogenic microorganisms into the blood system. This narrative review examines current evidence linking the use of tobacco with the dominance of pathogenic oral bacteria and a dysfunctional immune response. We explore how the chemicals and toxins in cigarettes promote a reduction in oxygen and cause changes in the abundance of anaerobic bacteria. After discussing the mechanistic pathways leading to periodontitis and the entry of microorganisms into the circulation, the review will interrogate previous studies and identify opportunities and priorities for future research.